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Abstract
Impairment of the ubiquitin-proteasome system (UPS) has long been considered an attractive hypothesis to explain the
selective dysfunction and death of neurons in polyglutamine disorders such as Huntington’s disease (HD). The fact that
inclusion bodies in HD mouse models and patient brains are rich in ubiquitin and proteasome components suggests that
the UPS may be hindered directly or indirectly by inclusion bodies or their misfolded monomeric or oligomeric precursors.
However, studies into UPS function in various polyglutamine disease models have yielded conflicting results, suggesting
mutant polyglutamine tracts may exert different effects on the UPS depending on protein context, expression level,
subcellular localisation and cell-type. To investigate UPS function in a well-characterised mouse model of HD, we have
crossed R6/2 HD mice with transgenic UPS reporter mice expressing the GFPu construct. The GFPu construct comprises GFP
fused to a constitutive degradation signal (CL-1) that promotes its rapid degradation under conditions of a healthy UPS.
Using a combination of immunoblot analysis, fluorescence and immunofluorescence microscopy studies, we found that
steady-state GFPu levels were not detectably different between R6/2 and non-R6/2 brain. We observed no correlation
between inclusion body formation and GFPu accumulation, suggesting no direct relationship between protein aggregation
and global UPS inhibition in R6/2 mice. These findings suggest that while certain branches of the UPS can be impaired by
mutant polyglutamine proteins, such proteins do not necessarily cause total blockade of UPS-dependent degradation. It is
therefore likely that the relationship between mutant polyglutamine proteins and the UPS is more complex than originally
anticipated.
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Introduction
Huntington’s disease (HD) is a neurodegenerative disorder
caused by the expansion of a polyglutamine tract in the N-
terminus of the 348 kDa protein huntingtin (htt). It is one of a
family of diseases caused by a polyglutamine expansion, and is
characterised by the misfolding, aggregation and deposition of
polyglutamine-expanded N-terminal htt into intracellular inclu-
sion bodies [1]. While mutant htt has been proposed to exert its
toxicity through various mechanisms including transcriptional
dysregulation [2] and disturbances to protein folding networks [3],
the finding that htt inclusion bodies are polyubiquitylated in
transgenic mice and HD patient brains has long suggested that
altered ubiquitin homeostasis or impaired ubiquitin-proteasome
system (UPS)-dependent protein degradation may contribute to
HD pathology [1,4].
The UPS is an essential cellular mechanism responsible for the
timely degradation of both healthy and damaged or misfolded
proteins. Degradation by the UPS requires that a protein is first
tagged with a minimum of four Lys48-linked ubiquitin monomers
before shuttling to and recognition by the 26S proteasome. The
26S proteasome is a multi-subunit and multi-catalytic machine
which unfolds, deubiquitylates, and digests its substrates into short
peptide fragments in an ATP-dependent manner [5]. Because of
its fundamental requirement to cellular viability, inhibition of any
of these steps as a result of protein aggregation or the inability to
handle specific toxic proteins could be responsible for the death
and dysfunction of neurons in HD and other polyglutamine/
protein conformation disorders [6].
It is becoming clear that disturbed ubiquitin homeostasis is
closely linked with HD pathology, as accumulation of polyubi-
quitin chains and increased levels of monoubiquitylated histone
H2A (uH2A) have been reported in HD mouse tissues [7–9]. It is
still currently unclear if mutant polyglutamine proteins cause a
general impairment of the UPS however. Assays of proteasome
activity using fluorogenic peptides exhibit normal or increased
proteasomal activity in brain extracts of various polyglutamine
disease mouse models [10–12], although human post-mortem HD
brains have shown diminished core proteasome activity [13]. In
support of a general blockade of UPS-dependent protein
degradation, it has been shown that the presence of a mutant
polyglutamine tract can hinder a protein’s proteasomal degrada-
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stretches may inactivate the 26S proteasome by becoming trapped
in the proteolytic chamber [16]. Adding credence to this
hypothesis was the report that eukaryotic proteasomes are unable
to degrade polyglutamine tracts [17]. However, recent data
demonstrates that polyglutamine tracts are degraded efficiently by
eukaryotic proteasomes, thereby refuting the proposal that mutant
polyglutamines block 26S proteasome function by becoming
trapped inside the 26S proteasome [18].
Biochemical assays have been very useful in rapidly assessing the
status of both 20S and 26S proteasome activity in polyglutamine-
disease tissue extracts by measuring degradation of non-ubiquity-
lated fluorogenic substrates and ubiquitylated-lysozyme substrates
respectively [10–13]. However, these assays do not involve
substrate passage through all steps of physiologically relevant
UPS-dependent protein degradation pathways. An alternative has
been the use of recombinant probes typically comprised of
enhanced green fluorescent protein (GFP) appended with a
destabilising modification which promotes their constitutive
degradation by the UPS [19,20]. Degradation signals utilised
have included the ubiquitin-fusion degradation (UFD) signal
[21,22], where an uncleavable N-terminal ubiquitin fusion directs
the protein to the UPS; the N-end rule signal [21], where certain
N-terminal amino acids cause rapid UPS-mediated protein
turnover; and the CL-1 degron [23], a destabilising C-terminal
16 amino acid sequence used to generate the ‘‘GFPu’’ UPS
reporter construct. The CL1 degron was originally identified in a
yeast screen for peptides that destabilise proteins in a manner
dependent on the E2 ubiquitin-conjugating enzymes Ubc6 and
Ubc7, but other E2s are also believed to promote CL-1
degradation in mammalian cells (reviewed in [19]). GFPu has
previously been shown to co-immunoprecipitate with ubiquitin
and accumulate when the proteasome is inhibited, supporting its
validity as a reliable UPS reporter [23]. Although each different
class of reporter requires different combinations of ubiquitin
conjugating (E2) and ligating (E3) enzymes and exhibit distinct
stabilities, they are all believed to converge on the same pool of
26S proteasomes. Assuming that the rates of synthesis of these
reporters are not perturbed, their steady-state levels in a given cell
type reflects overall flux through the UPS.
The first direct evidence that an expanded polyglutamine
protein can impair the UPS came from in vitro studies showing
mutant htt aggregation causes the accumulation of a stably-
expressed GFPu UPS reporter [23]. While similar observations
have been observed in cell models of other polyglutamine diseases
[24–26], no impairment was observed in a polyglutamine-
expanded ataxin-1 cell model using UFD or N-end rule UPS
reporters [27]. Impairment of the UPS has been observed in vivo in
a C.elegans spinocerebellar ataxia 3 (SCA3) model using a GFPu
UPS reporter [28], while contrasting evidence from an SCA7
mouse model shows that polyglutamine pathogenesis can occur in
the absence of significant UPS impairment, as detected by a UFD
reporter [29]. More recently, UPS impairment was observed in
synapses of transgenic R6/2 HD mouse neurons upon injection of
viral vectors harbouring the GFPu reporter [30]. Interestingly,
GFPu accumulation did not occur in neuronal cell bodies in this
study, suggesting that while subcellular localisation can affect UPS
efficiency in polyglutamine disease, mutant polyglutamine proteins
do not necessarily cause general impairment of the UPS.
In the current study, we have crossed transgenic R6/2 HD mice
[31] with transgenic GFPu mice [32] to investigate potential
impairment of the UPS in a well-established mouse model of HD.
We found that GFPu protein levels are unchanged in R6/2 whole
brain extracts, and that there is no accumulation of GFPu in R6/2
neurons relative to inclusion body formation. This suggests that
while mutant htt can cause disturbances to ubiquitin homeostasis
and in some cases impaired degradation of UPS substrates, it may
not necessarily cause a general blockade of UPS-dependent
protein degradation.
Results
Genetic cross of R6/2 transgenic HD mice with GFPu UPS
reporter mice
To test the hypothesis that mutant htt expression causes general
impairment of the UPS in vivo, we crossed the well-characterised
R6/2mouse model of HD [31] with GFPu UPS reporter mice [32],
which express the GFPu construct under the control of the mouse
prion promoter (Figure 1A). R6/2 mice express exon 1 of htt
harbouring a polyglutamine tract over 150 residues, and develop a
progressive neurological phenotype from around 4–5 weeks of age.
GFPu mice express the UPS reporter construct GFPu under the
controlofthemouseprionpromoter,whichaccumulatesincultured
mouse neurons under conditions of proteasome impairment [32].
GFPumaleswerecrossed with5-week-oldR6/2femalestogenerate
progeny of four genotypes to be used in subsequent experiments:
wild type (WT), R6/2, GFPu and R6/2; GFPu. Mouse brains were
harvested for analysis at 12 weeks, at which point R6/2 mice are at
an advanced stage of disease.
If general impairment of the UPS can be caused by the
expression of pathogenic polyglutamine proteins in vivo, then the
GFPu fusion protein should accumulate in the brains of R6/2;
GFPu mice. To investigate this possibility, GFPu levels were
compared between 12-week-old GFPu mice and double-transgenic
R6/2; GFPu mice. Western blot analysis of four whole-brain
lysates per genotype followed by densitometric quantification
revealed that the levels of GFPu were not altered in R6/2 mice
(Figure 1B), in agreement with lack of gross proteasome inhibition
in end-stage R6/2 brains [12]. To ensure that detection of
impairment of the UPS in R6/2 brains was not obscured by
dysregulated expression of the GFPu transgene, quantitative real-
time RT-PCR analysis was carried out to monitor expression of
GFPu mRNA. A GFP real-time expression assay was designed and
expression levels of GFPu were compared between four brains of
each genotype (GFPu and R6/2; GFPu). It was found that GFPu
mRNA expression was unchanged in R6/2; GFPu double-
transgenic mice (Figure 1C), suggesting the lack of difference in
GFPu protein levels in R6/2 mice is not confounded by altered
levels of GFPu mRNA.
Levels of native GFP fluorescence are unchanged in R6/2;
GFPu mice
Although western blot analysis of R6/2-GFPu mice suggested
that overall UPS function was normal in the R6/2 brain, it
remained possible that the UPS was impaired in specific brain
regions. To investigate this, sections of various gross brain regions
from 12-week-old R6/2-GFPu mice were analysed by confocal
microscopy. Sections were prepared side-by-side and confocal
settings were unchanged after initial correction for background
fluorescence in WT brains. Imaging of GFPu in the striatum,
cortex and hippocampus from four brains per genotype revealed
very comparable fluorescence levels between GFPu and R6/2;
GFPu (Figure 2), suggesting normal processing of GFPu in these
regions of the R6/2 brain. GFP fluorescence was widespread in
these regions suggesting that the GFPu fusion protein is present
throughout brain cells and neuronal processes, and the relatively
low level of native GFP fluorescence is likely due to the rapid
turnover of GFPu by the UPS. The GFPu protein appears to be
UPS Function in R6/2 Mice
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given that the prion promoter drives higher expression in neurons,
and suggests that transgene expression may have been influenced
by effects at the site of integration.
GFPu immunofluorescent intensity is unaltered in the R6/
2 brain
To confirm the results of the native GFPu imaging and to
quantify levels of GFPu, 12-week-old brain sections from R6/2-
GFPu mice were stained with an anti-GFP antibody and
fluorescently labelled secondary antibody. Preliminary experi-
ments confirmed that sections prepared for antibody staining did
not emit any native GFP fluorescence (data not shown). Images
captured from five brains per genotype suggested that there was no
difference in the amount of GFPu immunofluorescent staining in
the cortex, hippocampus or striatum between GFPu and R6/2;
GFPu mice, confirming that GFPu does not accumulate in these
regions in the R6/2 brain (Figure 3). To confirm that there was no
difference in GFPu levels in the R6/2 brain, fluorescent intensity
was carefully measured in each of the brain regions examined.
Fluorescent intensity in randomly selected areas of the striatum,
cortex and hippocampal neuronal layers was not significantly
different between GFPu and R6/2; GFPu genotypes, suggesting
an absence of general UPS impairment in the R6/2 brain
(Figure 3).
GFPu does not accumulate in neurons with inclusion
bodies
In contrast to native GFPu imaging, immunofluorescent
staining revealed a high concentration of GFPu in the densely-
packed neuronal layers of the hippocampus, including the dentate
gyrus and CA1 region, suggesting immunofluorescent staining
may be more sensitive to variations in GFPu levels than native
GFP fluorescence. To further investigate the possibility that GFPu
accumulates in neurons of the hippocampal CA1 region, and to
investigate any relationship between the UPS and inclusion body
formation, immunofluorescent double-staining of hippocampal
sections was performed with both anti-GFP and anti-htt antibody
S830. High magnification images revealed that GFPu levels were
similar between GFPu and R6/2; GFPu mice in the CA1 region,
despite widespread inclusion body formation in the R6/2 brain
(Figure 4). Although there was no gross accumulation of neuronal
GFPu in the R6/2 brain, it was important to determine whether
there was any relationship between inclusion body formation and
GFPu concentration. To this end, GFPu immunofluorescence was
compared between nuclei with or without an inclusion body in
three distinct brain regions. Visual examination of the images
suggested that there was no increase in GFPu concentration in
nuclei containing an inclusion body in the CA1 region of the
hippocampus, piriform cortex or cortex (Figure 5A). Quantifica-
tion of fluorescent intensity in at least four nuclei with or without
an inclusion body confirmed that the levels of GFPu did not
correlate with inclusion body formation in any of these regions in
Figure 1. GFPu does not accumulate in the R6/2 brain. (A)
Schematic showing the GFPu construct under control of the mouse
prion promoter (PrP). GFPu protein is composed of GFP appended with
a 16 amino acid C-terminal degradation signal, the CL-1 degron. (B)
Western blot analysis and densitomeric quantification reveals no
increase in steady-state levels of GFPu in 12 week R6/2 brains. a-
tubulin was used as a loading control. (C) Expression of the GFPu
transgene is unchanged in the 12-week-old R6/2 brain. Error bars
represent the standard error of the mean.
doi:10.1371/journal.pone.0005128.g001
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relationship between the aggregation of mutant htt and the
efficiency of the UPS in vivo.
Discussion
In this study, we have set out to investigate UPS function in the
R6/2 mouse model of HD, using the degradation of the artificial
UPS substrate GFPu as a reporter of in vivo UPS activity. We
found by immunoblot analysis that steady-state levels of GFPu
were unchanged in the R6/2 brain, in keeping with the normal
extractable in vitro degradative capacity of proteasomes [12]. In
agreement, immunofluorescence studies demonstrated that there is
no net accumulation of GFPu in different regions of the R6/2
brain. The pyramidal neurons of the hippocampal CA1 region
were examined at high magnification for any change in GFPu
immunofluorescence levels in R6/2 mice. However, GFPu levels
were not significantly different in R6/2 mice despite widespread
inclusion body formation. Further analysis suggested that there
was no correlation between GFPu levels and inclusion body
formation in R6/2 neurons.
Notwithstanding any limitations of GFPu as a sensitive reporter of
UPS function therefore, we have failed to detect a global inhibition of
the UPS in R6/2 HD mice. As a surrogate measure of UPS activity
Figure 2. Native GFPu fluorescence in R6/2-GFPu mice. Native GFPu fluorescence is not notably increased in the hippocampus, cortex or
striatum of R6/2; GFPu mice. Sections were stained with the nuclear-specific fluorescent dye TOPRO-3. Scale bars are 40 mM.
doi:10.1371/journal.pone.0005128.g002
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could be affected such that its steady-state levels are not an accurate
representation of global UPS activity. For example, the synthesis of
GFPu protein may be delayed as a result of polyglutamine
pathogenesis or proteins may associate with the CL-1 degron
differently between WT and R6/2 neurons, thereby differentially
affecting GFPu stabilisation. However, previous work with cultured
c o r t i c a ln e u r o n sf r o mG F P um i c es h o w e dt h a tG F Pf l u o r e s c e n c e
accumulated in response to proteasome inhibition in a dose-
dependent manner [32], and stereotaxic injection of the proteasome
inhibitor MG-132 to GFPu mouse brains also lead to GFPu
accumulation (manuscript in preparation). This suggests that in vivo,
steady-state levels of GFPu are likely to act as a reliable indicator of
global UPS function. In addition, our study is in agreement with
recent studies by Wang et al., who showed that while UPS function
may be compromised inR6/2 synapses,the GFPufusion proteinwas
degraded normally in the cell body [30]. This observed impairment
of the UPS in R6/2 cell synapses [30] coupled with the finding that
K48-linked polyubiquitin chains accumulate in R6/2, Hdh
Q150/Q150
HDknock-in miceand HD patient brains[7]suggeststhatwhile UPS
impairment can occur as a consequence of mutant htt expression, it is
not necessarily a global consequence of mutant htt expression.
Although we cannot rule out the possibility that we have failed to
detect general UPS impairment due to technical limitations of our
GFPu measurements, the current study is in agreement with another
that failed to detect UPS impairment in an SCA7 model using a
UFD-based GFP reporter [29], a reporter that successfully detected
UPS impairment in prion-infected mice [33].
While it is clear that the UPS is an important cellular defence
against toxic polyglutamine protein expression [34], it is less clear
Figure 3. GFPu immunofluorescence in R6/2-GFPu mice. Immunofluorescent staining of brain sections with anti-GFP antibody followed by
quantitation of fluorescent units reveals no difference in the levels of GFPu in R6/2 cortex (A), hippocampus (B) or striatum (C). Sections were
counterstained with the nuclear fluorescent dye TOPRO-3. Error bars represent the standard error of the mean. Scale bars are 40 mM.
doi:10.1371/journal.pone.0005128.g003
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polyglutamine proteins. Early hypotheses suggested mutant poly-
glutamine proteins could inhibit the 26S proteasome through
undegradable polyglutamine stretches becoming trapped inside the
proteasome proteolytic chamber [16]. In favour of this, it has been
shown that polyglutamine proteins are intrinsically difficult to
degrade [14,15] and it has been reported that eukaryotic
proteasomes are unable to degrade within polyglutamine tracts
[17]. However, conflicting results have shown that polyglutamine
tracts are cleaved at multiple sites by eukaryotic proteasomes [18],
and targeting mutant polyglutamine proteins to the UPS is sufficient
for their degradation [35,36]. In addition, the fact that extractable
26S proteasome activity is normal in R6/2 brains [12] and the
current findingthatGFPusteady-state levelsareunchanged inR6/2
neurons suggests that any impairment of the UPS caused by mutant
polyglutamines does not occur through direct blockage of the 26S
proteasome. This is supported by the in vitro finding that impairment
of the UPS can occur in the nucleus and cytoplasm irrespective of
the compartment to which mutant htt is restricted [25]. Any
impairment of the UPS which may occur in for example, the
synapse, may in fact be secondary to local reductions in ATP or
axonal transport defects [30]. However, it has also been shown that
while inclusion bodies themselves do not impair UPS function [25],
filamentous aggregates purified from HD brains are capable of
impairing the 26S proteasome in vitro [37].
The roots of the discrepancies in UPS efficiency observed
between different model polyglutamine-disease systems are
unclear. Using fluorescent UPS reporters, impairment of the
UPS has been observed in some cell models [23,24,26] but not
others [27]. In addition, global UPS impairment has been
reported in a C.elegans polyglutamine disease model [28] but not
in mouse models [29]. It is possible therefore, that mutant
polyglutamine proteins do not necessarily cause a global
impairment of the UPS, but rather may affect certain branches
of the UPS depending on expression levels, cell type and
subcellular localisation. The growing evidence for the involvement
of UPS impairment in other neurodegenerative protein confor-
mation disorders such as prion and Parkinson’s disease [33,38]
may not therefore be directly applicable to the polyglutamine
diseases. However, disturbances in ubiquitin homeostasis are
emerging as being closely linked to polyglutamine disease
progression [7,9]. In addition to proteolysis, protein ubiquitylation
affects a diverse range of cellular processes such as transcription,
DNA repair, endocytosis, so perturbations in the ubiquitin system
are likely to have global cellular consequences. It is very likely that
elucidating the role of disturbed ubiquitin homeostasis in HD and
the polyglutamine diseases will be informative with respect to
unravelling the molecular pathology of these disorders.
Materials and Methods
Mouse husbandry
Mice were housed and experimental procedures performed in
accordance with Home Office regulations. Animals had unlimited
access to water and number 3 rodent breeding chow (Special Diet
Services, Witham, UK), and were subject to a 12 h light (08:00–
20:00), 12 h dark (20:00–08:00) cycle. Mice were housed 5 to a cage
with environmental enrichment in the form of paper shred bedding
(Enviro-dri, Lillico, Betchworth, UK), a play tunnel (Datesand Ltd.,
Manchester, UK) and wood shavings (GLP Aspen Chips, Datesand
Ltd., Manchester, UK). R6/2 transgenic HD mice were generated as
described previously [31]. The R6/2 mouse colony was maintained
by backcrossing R6/2 males to (C57BL/6JxCBA/Ca) F1 females
(B6CBAF1/OlaHsd, Harlan Olac, Bichester, UK). GFPu mice were
generated as previously described [32] and maintained on a C57BL/
6J background (Harlan Olac, Bichester, UK).
Western blot analysis
Mice were culled by cervical dislocation and brains snap frozen
in isopropanol on dry ice. Brain hemispheres were homogenised in
sodium phosphate buffer [20 mM sodium phosphate pH 7.4, 1%
SDS and complete protease inhibitors (Boehringer Mannheim)]
and sonicated for 30 s. Protein concentration was measured using
the BCA (bicinchoninic acid) assay kit (Pierce) and 20 mg protein
was loaded onto 10% SDS-polyacrylamide gels before transfer to
nitrocellulose membrane for immunoblotting. Following transfer,
membranes were rinsed in PBS and then incubated for 1 h in 5%
non-fat dry milk (NFDM) in PBS on a shaker. Membranes were
probed with anti-GFP antibody (Abcam, 1:1000) in 5% NFDM for
2 h at room temperature then rinsed four times in PBS on a shaker
for 5 min per wash before incubation with horse radish peroxidase
(HRP)-linked anti-rabbit secondary (Amersham, 1:3000) in 5%
NFDM. Membranes were then washed four times in PBS and
protein was detected using the Enhanced Chemiluminescence
(ECL) kit and Hyperfilm ECL (Amersham). Membranes were
stripped in stripping buffer (100 mM b-mercaptoethanol, 2%
SDS, 62.5 mM and Tris.HCl pH 6.7) at 50uC for 20 min with
occasional agitation and reprobed with anti-a-tubulin (Sigma,
1:2000) and HRP-linked anti mouse secondary (Vectastain,
1:5000). ECL immunoblot signals were quantified on a Bio-Rad
GS-800 Calibrated Densitometer using Quantity-OneH software.
Protein levels of four brains per genotype were quantified in three
independent experiments and Student’s t-test was performed to
compare protein levels between genotypes.
Quantitative real-time RT-PCR analysis
Mice were sacrificed by cervical dislocation and brains were
quickly dissected, frozen in isopentane on dry ice and stored at
280uC until required. Total RNA was extracted from whole brain
using the RNeasy lipid mini kit (Qiagen). Quality and quantity of
Figure 4. GFPu immunofluorescence and inclusion body
formation in the hippocampus. GFPu immunofluorescence in the
CA1 region of the hippocampus is comparable in 12-week-old GFPu
and R6/2; GFPu brains. Staining with anti-htt antibody S830 shows
widespread inclusion body formation in R6/2 mice. Sections were
stained with the nuclear fluorescent dye TOPRO-3. Scale bars are 10 mM.
doi:10.1371/journal.pone.0005128.g004
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BioAnalyzer according to the manufacturer’s instructions (Agilent
Technologies). Reverse transcription of total brain RNA into
single-stranded cDNA was carried out in two steps. First, 1 mg
RNA was incubated with 100 ng random hexamer nucleotides
and 100 mM DTT in diethylpyrocarbonate (DEPC)-treated H20
(Ambion) at 94uC for 90 s. The reaction was then incubated on ice
for 2 min before reverse transcription was carried out in 20 ml
total volume in the presence of 1 mM dNTPs, 10 U RNAsin, 200
U MMLV RTase (Moloney Murine Leukaemia Virus reverse
transcriptase) and 1
st strand buffer (Invitrogen). Cycling conditions
were 23uC 10 min, 37uC 40 min and 94uC 5 min before cDNA
was diluted 12.5-fold in nuclease-free water. Quantitative real-time
RT-PCR was carried out for each gene using the Opticon 2 real-
time PCR machine (MJ Research) in a 25 ml reaction containing
400 nM primers, 200 nM probe and QuantiTect Probe PCR mix
(Qiagen). Primer and probe sequences were as follows: forward 59-
CTG AGC AAA GAC CCC CAA CGA-39, reverse 59-GGC
GGC GGT CAC GAA-39 and probe 6-FAM-CGC GAT CAC
ATG GTC CTG CTG G-TAMRA. Cycling conditions were:
50uC 2 min, 95uC 15 min, 396 (94uC1 5s ,6 0 uC 60 s). Each
sample was amplified in triplicate and mRNA estimation was
made by comparison to duplicate standard curves and normalisa-
tion to b-actin [9].
Figure 5. Relationship between the UPS and inclusion formation. (A) Immunofluorescent double-staining of R6/2; GFPu brain sections shows
that the presence of nuclear inclusion bodies does not correlate with the intensity of GFPu immunofluorescence in CA1 region of the hippocampus,
the piriform cortex or the cortex (B). Quantification of GFPu immunofluorescence in nuclei with or without an inclusion body confirms that there is no
relationship between inclusion body formation and impairment of the UPS in R6/2 mice. Sections were stained with the nuclear fluorescent dye
TOPRO-3. Error bars represent the standard errors of the mean. Scale bars are 6 mM.
doi:10.1371/journal.pone.0005128.g005
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microscopy
For native GFP imaging, mice were transcardially perfused with
4% PFA after wash-through with PBS. Brains were carefully
dissected and post-fixed in 4% PFA at 4uC overnight, then
transferred to 30% sucrose in PBS and stored at 4uC overnight.
Brains were embedded in OCT Compound (Tissue-Tek) and
stored at 280uC until required. Coronal sections were cut to a
thickness of 15 mm using a cryostat and delicately placed on
Polysine slides (VWR international) in darkness and stored at
280uC until required. Sections were stained with the nuclear dye
TOPRO-3 (Invitrogen, 1:1000) and viewed on a Zeiss LSM510
confocal microscope. For immunofluorescence, mice were sacri-
ficed by cervical dislocation and brains were quickly removed,
frozen in isopentane on dry ice and stored at 280uC until
required. Coronal sections were cut to a thickness of 15 mm using
a cryostat (Bright Instrument Co. Ltd, UK), delicately placed on
Polysine slides and stored at 280uC until required. Sections were
fixed in 4% paraformaldehyde (PFA) for 30 min and washed in
two changes of dH20 before blocking for 15 min with 2% BSA in
PBS. Sections were incubated with TOPRO-3, anti-GFP (Novus
Biologicals, 1:1000) and/or S830 anti-htt [39] (1:2000) primary
antibodies at 4uC overnight in darkness and washed in PBS for
15 min with gentle shaking. Fluorescent secondary antibodies
Alexa-488-conjugated anti-rabbit (Molecular Probes, 1:1000) and
Alexa-555-conjugated anti-sheep (Molecular Probes, 1:1000) were
then incubated with the sections for 1 h at room temperature in
darkness, followed by a 15 min wash in PBS with gentle shaking.
Antibodies were diluted in 2% BSA in PBS. Sections were
mounted with Mowiol-488 (Calbiochem) and viewed on a Zeiss
LSM150 confocal microscope. For native and immunofluores-
cence studies, optimal confocal settings were obtained to limit
background fluorescence and ensure detected fluorescent signals
were not saturated, and remained the same throughout the
experiment. Serial sections for native fluorescence detection were
taken from four brains per genotype and for immunofluorescence
studies from five brains per genotype. To quantify immunofluo-
rescence of GFP-stained brain sections, fluorescent intensity
measurements were taken of a fixed area between sections and
within images using software supplied with the LSM510 confocal
microscope. Once a fixed area had been established, areas of brain
images were selected at random from different sections from
different brains and the fluorescent intensity value was recorded.
For quantification of fluorescence within nuclei, the size of the
area chosen was enough to closely accommodate nuclei. Student’s
t-test was used to compare immunofluorescent intensity.
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